Revised forecast
Fiscal year ending January 2027 · Full yearPrevious forecast published Announced on 17 March 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The revision reflects a plan to proceed with a cautious introduction of Akugo®, primarily at medical institutions that conducted the clinical trials, on the assumption that the proposed drug price will be adopted. Operating profit reflects the increase in business revenue, ordinary profit reflects foreign exchange gains on foreign-currency-denominated loans and other items, and net income attributable to owners of the parent reflects the income taxes adjustments associated with recognition of deferred tax liabilities.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥396 million |
| Operating profit | ¥-5,625 million → ¥-5,229 million |
| Ordinary income | ¥-5,632 million → ¥-5,074 million |
| Profit attributable to owners of the parent | ¥-5,635 million → ¥-5,133 million |
| Net income per share | -72.21 yen → -65.77 yen |
| Fiscal Period Covered | Fiscal year ending January 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | Announced on 17 March 2026 |
| Previous-period results | Operating loss: ¥3,794 million; ordinary loss: ¥4,291 million; net loss attributable to owners of the parent: ¥3,842 million; net loss per share: ¥52.55 |
| Reason for the revision | The revision reflects a plan to proceed with a cautious introduction of Akugo®, primarily at medical institutions that conducted the clinical trials, on the assumption that the proposed drug price will be adopted. Operating profit reflects the increase in business revenue, ordinary profit reflects foreign exchange gains on foreign-currency-denominated loans and other items, and net income attributable to owners of the parent reflects the income taxes adjustments associated with recognition of deferred tax liabilities. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The earnings forecast reflects a plan to introduce Akugo® cautiously, primarily at medical institutions that conducted the clinical trials, on the assumption that the proposed drug price will be adopted. Operating profit reflects the increase in business revenue, ordinary profit reflects foreign exchange gains on foreign-currency-denominated loans and other items, and net income attributable to owners of the parent reflects the income taxes adjustments associated with recognition of deferred tax liabilities.